logo

For the Inventor, By the Inventor

Rockledge, PA, United States of America

Ilya G Serebriiskii

This inventor holds 8 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Fox Chase Cancer Center, Institute for Cancer Research, Georgetown University. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ilya G Serebriiskii. Retrieved from https://idiyas.com/inventor/ilya-g-serebriiskii

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 87.5

 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 33(Granted Patents)


Location History:

  • Rockledge, PA (US) (2011 - 2019)
  • Philadelphia, PA (US) (2001 - 2020)

Company Filing History:

goldMedal4 out of 81 
 
Fox Chase Cancer Center
 patents
silverMedal3 out of 69 
 
Institute for Cancer Research
 patents
bronzeMedal2 out of 499 
 
Georgetown University
 patents
4. 1 out of 6 
 
Nexuspharma, Inc.
 patents
5. 1 out of 3,076 
 
The General Hospital Corporation
 patents
where one patent can have more than one assignee

Years Active: 2001-2026

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents
1. 12674206 - Systems and methods for treating patients having a genetic predisposition to develop prostate cancer (2026-07-07),
2. 10724100 - Systems and methods for treating patients having a genetic predisposition to develop prostate cancer (2020-07-28),
3. 10450613 - EGFR/NEDD9/TGF-β interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders (2019-10-22),
4. 10328050 - C-Myc as a biomarker for tumor sensitivity to treatment with RNA polymerase II inhibition (2019-06-25),
5. 9677072 - Methods of inhibiting proliferation of estrogen-independent cancer cells (2017-06-13),
6. 9101631 - Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer (2015-08-11),
7. 7919610 - Yeast bacterial two-hybrid system and methods of use thereof (2011-04-05),
8. 6326150 - Yeast interaction trap assay (2001-12-04),

Title: Ilya G. Serebriiskii: Innovator in Cancer Treatment

Introduction

Ilya G. Serebriiskii is a prominent inventor based in Rockledge, PA (US), known for his significant contributions to cancer research and treatment. With a total of seven patents to his name, he has made strides in developing innovative systems and methods aimed at addressing genetic predispositions to prostate cancer.

Latest Patents

Among his latest patents, Serebriiskii has developed systems and methods for treating patients with a genetic predisposition to develop prostate cancer. These methods involve evaluating peripheral blood cells for the presence or quantity of gamma-H2AX foci and gene alterations that correlate with prostate cancer development. His work also includes the identification of agents effective in treating hyperproliferative disorders through the EGFR/NEDD9/TGF-β interactome.

Career Highlights

Serebriiskii has worked with esteemed institutions such as the Fox Chase Cancer Center and the Institute for Cancer Research. His research has focused on the intricate mechanisms of cancer development and the potential for targeted therapies.

Collaborations

Throughout his career, Serebriiskii has collaborated with notable colleagues, including Erica A. Golemis and Igor Astsaturov. These partnerships have furthered his research and contributed to advancements in cancer treatment methodologies.

Conclusion

Ilya G. Serebriiskii's innovative work in cancer research exemplifies the impact of dedicated inventors in the medical field. His patents and collaborations continue to pave the way for new treatment options for patients facing genetic risks of prostate cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…